Salt AI, a leader in contextual AI for enterprise applications, has raised $10 million to enhance its platform for biopharma and healthcare industries. This funding will drive innovation in drug discovery and clinical development.
Salt AI secures $10 million in funding led by Morpheus Ventures.
Capital to expand AI solutions for biopharma and healthcare sectors.
Platform enhances drug discovery, clinical development, and operations.
Ellison Medical Institute leverages Salt AI for computational biology.
Salt Matrix offers intuitive, sector-specific AI workflow tools.
Focus on visual collaboration, speed, and enterprise-grade compliance.
Salt AI's $10 million funding round, led by Morpheus Ventures with participation from Struck Capital, Marbruck Investments, and CoreWeave, will accelerate its mission to transform life sciences. The capital will expand its customer base among leading biopharma and healthcare companies, while scaling global AI engineering teams to deliver impactful solutions. This investment underscores the growing demand for AI-driven workflows in drug discovery, clinical development, and enterprise operations.
The Ellison Medical Institute (EMI) exemplifies Salt AI’s impact, using the platform since summer 2024 to advance computational biology. EMI has accelerated drug discovery by designing and analyzing thousands of compounds, with two protein candidates progressing to wet-lab studies by August 2025. “Salt AI represents a transformative advance in the computational biology stack,” said Dr. David Agus, Founding CEO of the Ellison Medical Institute. “By combining drag-and-drop workflows with transparent AI integration, the platform enables a new paradigm of therapeutic design, one that is faster, more efficient, and highly data-driven.”
Central to Salt AI’s platform is the Salt Matrix, a catalog of sector-specific data connectors, models, and solutions. This enables rapid creation of AI workflows through intuitive drag-and-drop tools. The platform emphasizes visual collaboration, allowing scientists, technologists, and executives to bridge the “bilingual talent” gap. It also ensures speed to value with deployments in days and offers a compliant stack for enterprise-grade adoption, integrating proprietary data and workflows seamlessly.
Salt AI’s platform supports a range of applications, from protein generation and biomarker discovery to clinical evidence synthesis and diagnostics. “We are in the midst of a breakthrough moment in life sciences, with AI igniting unprecedented opportunities that were once out of reach,” said Aber Whitcomb, CEO and Co-Founder of Salt AI. “No single AI model can unlock the future of medicine alone. The future belongs to ensembles, models working in synergy.” This vision positions Salt AI as a key player in advancing healthcare innovation.
Salt AI’s focus on scalability and compliance ensures its solutions meet the rigorous demands of enterprise environments. By empowering cross-functional teams, the platform drives measurable outcomes, as seen in EMI’s accelerated drug discovery process. With this funding, Salt AI is poised to redefine AI’s role in life sciences.
Salt AI’s $10 million funding marks a significant step toward revolutionizing AI applications in life sciences. By combining intuitive tools, enterprise-grade compliance, and rapid deployment, the platform empowers biopharma and healthcare organizations to achieve breakthroughs. As Salt AI expands its global reach, its impact on drug discovery and clinical outcomes will continue to grow, shaping the future of healthcare innovation.
Salt AI is the collaborative operating system for life sciences, enabling research and healthcare teams to rapidly integrate, visualize, and deploy AI models. From protein generation and biomarker discovery to clinical evidence synthesis and diagnostics, Salt AI combines enterprise-grade scalability with a visual-first interface, empowering cross-functional teams to accelerate discovery and innovation. Founded by successful serial entrepreneurs with a track record of building category-defining platforms, Salt AI is redefining how AI supports discovery and care at scale.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.